mention in the smh, page-5

The 'Immunotherapy " field of treatment for cancer is somewhat ' novel '

... It is rapidly gaining more and more acceptance as a legimate treatment and adjunct to the treatment of cancers ......

... and thanks to Dendreon's breakthrough in achieving FDA approval for it's Immunotherapy treatment of Provenge ... Its market capital has somewhat dimi nished through what could loosely be termed " over promising and underachieving' .. and a nosediving sharemarket divesting itself from risk... there is nothing wrong with the product ....

... interesting as of today's closing market capital comparisons between Prima Biomed ( $156 million ) and Dendereon ($1,510 million / $ 1.51 billion ) ... DNDN is 9.7 x the Market Cap of PRR .....

...as the markets gradually and eventually find their feet ... and Dendreon sorts out its medicare funding and production isssues ... it will indeed ... like the Phoenix ... rise from the ashes ...

Prima is interestingly in a great space right now ... despite having it's share price hammered of late ... it too will rise ... its has always been a long term play ... period ... I

... it has only been since PRR's somewhat meteoric rise in late December last year that has been a magnet for those seeking ' instant gratification ' ... of a rapidly ascending share price ....

... and the drawing in of traders and those with a shorter term focus on events ....

For myself and many others who do have these 'babies' in the bottom drawer ... basically not much has changed ... except the small FACT that funding for the final leg in the process ... Phase 111 trials ... IS FULLY FUNDED ....

whilst many doubted the wisdom of the capital raising for these trials at the time ... to the detriment of Prima's immediate share price ... the long term focus for these fund managers and many retail investors.... is one which is possibly at least 1 or 2 years away ... and a great opportunity to indeed double, triple, quadruple ... or even greater multiply one's investment ...

... never lose sight of the long term focus... if indeed your's is truly a long term hold .